<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6095">
  <stage>Registered</stage>
  <submitdate>13/09/2016</submitdate>
  <approvaldate>13/09/2016</approvaldate>
  <nctid>NCT02908815</nctid>
  <trial_identification>
    <studytitle>Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease</studytitle>
    <scientifictitle>Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>B2016:077</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - rTMS active treatment
Treatment: devices - rTMS sham treatment

Experimental: 4 weeks active treatment - 4 weeks of rTMS active treatment applied using an active rTMS coil.

Experimental: 2 weeks active treatment - 2 weeks of rTMS active treatment applied using an active rTMS coil.

Sham Comparator: 4 weeks sham treatment - 4 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.


Treatment: devices: rTMS active treatment
Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.

Treatment: devices: rTMS sham treatment
A fake treatment designed to mimic the sensations of rTMS

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) change - Standard measure of cognitive symptoms, a popular tool that measures the severity of dementia symptoms. The primary outcome measure will be the change in the score from the baseline at 5 weeks.</outcome>
      <timepoint>Weeks 0 and 5</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Stroop Test - Measures a person's attention by having them read colour names when the colour of the text doesn't match.</outcome>
      <timepoint>Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Digit Span Test - Memory test asking the participant to remember a sequence of numbers and repeat them back.</outcome>
      <timepoint>Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>1-Back Test - Memory and attention test where participant needs to recall the previous value and identify if it matches the current one.</outcome>
      <timepoint>Weeks 0, 3, and 5, and then every 8 weeks following end of treatment (six total assessments)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Verbal Fluency Test (VFT) - Fluency test where the participant has to name as many words a possible that match a certain criteria.</outcome>
      <timepoint>Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neuropsychiatric Inventory-Questionnaire (NPI-Q) - Caregiver questionnaire that assesses severity of symptoms</outcome>
      <timepoint>Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) - Caregiver questionnaire that assesses patient's ability to handle daily activities</outcome>
      <timepoint>Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Zarit Burden Interview (ZBI) - Caregiver questionnaire that assesses the burden of the patient on the caregiver</outcome>
      <timepoint>Weeks 0, 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Satisfaction Questionnaire for Medication (TSQM) - Assessment that asks directly if the participant is satisfied with the treatment</outcome>
      <timepoint>Weeks 3, 5, 11, 19, and 27 for the 2 week group and weeks 0, 3, 5, 13, 21, and 29 for the 4 week groups</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) effect over time - Standard measure of cognitive symptoms, a popular tool that measures the severity of dementia symptoms.</outcome>
      <timepoint>Weeks 0, 3, 11, 19, and 27 for the 2 week group and weeks 0, 3, 13, 21, and 29 for the 4 week groups</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Individuals must have a MoCA score between 7 and 25, indicating mild cognitive
             impairment or dementia, a CDR score of 1-2, and a CSDD score of 18 or less.

          -  Participants must have probable early or moderate Alzheimer's disease as confirmed by
             their treating neurologist or psychiatrist, and/or by the co-investigators: Dr.
             Modirrousta, Dr. Omelan, Dr. Mansouri or Dr. Millikin.

          -  Participants must be taking a stable dose of an acetylcholinesterase inhibitor for at
             least 3 months prior to study entry with no plans to change medication for the
             duration of the study.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Psychiatric conditions/disorders, or current neurological or medical disorders, other
             than AD, that could interfere with the subjects' cooperative participation (e.g.
             Severe agitation, prominent anxiety)

          -  Mental retardation

          -  Impaired visual and auditory acuity that confounds performance in cognitive tests

          -  Being diagnosed explicitly by other forms of dementia

          -  Confounding psychiatric disorders (e.g., schizophrenia, bipolar affective disorder) or
             current neurological, systemic, or medical disorders (e.g., liver disease, congestive
             heart failure, severe COPD) that may impair cognition and/or could affect attention
             span.

          -  Use of benzodiazepines or other hypnotics during the study and preceding two weeks

          -  Use of drugs with anticholinergic properties

          -  Pharmacological immunosuppression

          -  Participation in a clinical trial with any investigational agent within two weeks
             prior to study enrollment

          -  Current alcohol abuse

          -  History of epileptic seizures or epilepsy

          -  Contraindication for receiving TMS treatment according to a TMS questionnaire.

          -  Clinically significant abnormal laboratory findings which have not been approved by
             the Principal Investigator.

          -  Inability to adequately communicate in English in Manitoba and Australia sites and
             either English or French in Montreal site.

          -  Previous treatment with rTMS within the past 3 months

          -  A change in medication for AD, mood disorders, or pain during the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/11/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash University - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Manitoba</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Weston Brain Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main objective of this study is to investigate the effects of repetitive Transcranial
      Magnetic Stimulation (rTMS) treatment on patients with probable early or moderate Alzheimer's
      disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02908815</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Zahra Moussavi, PhD</name>
      <address />
      <phone>204-474-7023</phone>
      <fax />
      <email>Zahra.Moussavi@umanitoba.ca</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>